{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:39:16Z","timestamp":1783456756694,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20220902"],"award-info":[{"award-number":["DFL20220902"]}]},{"name":"Clinical Trials Foundation of Peking University Cancer Hospital","award":["QNJJ202108"],"award-info":[{"award-number":["QNJJ202108"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to investigate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective, single-center, single-arm study, we enrolled patients (18\u201370 years) with 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1r-IVA and IVB (distant metastasis only with inguinal lymph node metastasis) cervical cancer. Eligible patients should have normal function of the bone marrow (absolute neutrophil count (ANC)\u2009\u2265\u20092.0\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L) and adequate hepatic and renal functions. Key exclusion criteria included: previous chemotherapy and\/or radiotherapy; a history of bone marrow dysplasia or other hematopoietic abnormalities. All patients underwent radical radiotherapy (pelvic radiotherapy or extended-field irradiation) plus brachytherapy. The chemotherapy regimen included four cycles of 3-weekly paclitaxel and cisplatin. PEG-rhG-CSF was administered 48\u201372\u00a0h after each treatment cycle. Salvage granulocyte colony-stimulating factor (G-CSF) was only permitted in certain circumstances. The primary endpoint was the incidence of grade 3\u20134 neutropenia. The secondary endpoints included frequency of febrile neutropenia (FN), chemotherapy completion rate in cycles 2\u20134, time to complete radiotherapy, and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 52 patients were enrolled in this study from July 2019 to October 2020. The incidence of grade 3\u20134 neutropenia was 28.8%, with an average duration of grade 3\u20134 neutropenia persistence of 3.85 days (1\u20137 days). The incidence rate of FN was 3.8%. The chemotherapy completion rate was 94.2%, 82.7%, and 75.0% for cycles 2\u20134, respectively. The incidences of grade 3\u20134 neutropenia for cycles 1\u20134 were 9.6% (5\/52), 8.2% (4\/49), 14.0% (6\/43), and 2.6% (1\/39), respectively. All patients completed radiotherapy within 8 weeks (median, 48 days; range: 41\u201356 days), except one patient who withdrew consent and did not receive radiotherapy. Severe non-hematologic toxicity was not observed in any patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PEG-rhG-CSF is an effective and safe prophylactic treatment for neutropenia in patients with cervical cancer undergoing concurrent chemoradiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry, ChiCTR1900024494. Date of Registration:13\/July\/2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12556-4","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:02:45Z","timestamp":1720771365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jing","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"12556_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332. https:\/\/doi.org\/10.3322\/caac.21338.","journal-title":"CA Cancer J Clin"},{"key":"12556_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","volume":"340","author":"M Morris","year":"1999","unstructured":"Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137\u201343. https:\/\/doi.org\/10.1056\/NEJM199904153401501.","journal-title":"N Engl J Med"},{"key":"12556_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","volume":"340","author":"PG Rose","year":"1999","unstructured":"Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144\u201353. https:\/\/doi.org\/10.1056\/NEJM199904153401502.","journal-title":"N Engl J Med"},{"key":"12556_CR4","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802\u201312. https:\/\/doi.org\/10.1200\/JCO.2008.16.4368.","journal-title":"J Clin Oncol"},{"key":"12556_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ijrobp.2019.03.038","volume":"104","author":"LT Tan","year":"2019","unstructured":"Tan LT, P\u00f6tter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, et al. Change in patterns of failure after image-guided brachytherapy for cervical cancer: analysis from the RetroEMBRACE study. Int J Radiat Oncol Biol Phys. 2019;104:895\u2013902. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12556_CR6","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","volume":"29","author":"A Due\u00f1as-Gonz\u00e1lez","year":"2011","unstructured":"Due\u00f1as-Gonz\u00e1lez A, Zarb\u00e1 JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678\u201385. https:\/\/doi.org\/10.1200\/JCO.2009.25.9663.","journal-title":"J Clin Oncol"},{"key":"12556_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2019.04.013","volume":"154","author":"S Ma","year":"2019","unstructured":"Ma S, Wang J, Han Y, Guo F, Chen C, Chen X, et al. Platinum single-agent vs. platinum-based Doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: a meta-analysis of randomized controlled trials. Gynecol Oncol. 2019;154:246\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.013.","journal-title":"Gynecol Oncol"},{"key":"12556_CR8","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158\u201367. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823.","journal-title":"J Clin Oncol"},{"key":"12556_CR9","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","volume":"28","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914\u201324. https:\/\/doi.org\/10.1200\/JCO.2009.25.8723.","journal-title":"J Clin Oncol"},{"key":"12556_CR10","unstructured":"National Comprehensive Cancer Network. Hematopoietic growth factors. Version 2.2023. https:\/\/www.nccn.org\/guidelines."},{"key":"12556_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/IGC.0000000000000744","volume":"26","author":"MI Mart\u00ednez-Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez-Fern\u00e1ndez MI, Legaspi Folgueira J, Valtue\u00f1a Peydr\u00f3 G, Cambeiro M, Espin\u00f3s J, Aramend\u00eda JM, et al. Long-term results of a phase II trial of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer. Int J Gynecol Cancer. 2016;26:1162\u20138. https:\/\/doi.org\/10.1097\/IGC.0000000000000744.","journal-title":"Int J Gynecol Cancer"},{"key":"12556_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"G Molineux","year":"2004","unstructured":"Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235\u201344. https:\/\/doi.org\/10.2174\/1381612043452613.","journal-title":"Curr Pharm Des"},{"key":"12556_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-017-4609-6","volume":"168","author":"J Xie","year":"2018","unstructured":"Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Res Treat. 2018;168:389\u201399. https:\/\/doi.org\/10.1007\/s10549-017-4609-6.","journal-title":"Breast Cancer Res Treat"},{"key":"12556_CR14","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.7150\/jca.31538","volume":"10","author":"X Liu","year":"2019","unstructured":"Liu X, Meng Q, Wang W, Zhou Z, Zhang F, Hu K. Predictors of distant metastasis in patients with cervical cancer treated with definitive radiotherapy. J Cancer. 2019;10:3967\u201374. https:\/\/doi.org\/10.7150\/jca.31538.","journal-title":"J Cancer"},{"key":"12556_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12885-021-08364-9","volume":"21","author":"D Zou","year":"2021","unstructured":"Zou D, Guo M, Zhou Q. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer. BMC Cancer. 2021;21:661. https:\/\/doi.org\/10.1186\/s12885-021-08364-9.","journal-title":"BMC Cancer"},{"key":"12556_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/jjco\/hyy113","volume":"48","author":"S Yanazume","year":"2018","unstructured":"Yanazume S, Karakida N, Higashi R, Fukuda M, Togami S, Kamio M, et al. Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy. Jpn J Clin Oncol. 2018;48:892\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyy113.","journal-title":"Jpn J Clin Oncol"},{"key":"12556_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2021.01.025","volume":"153","author":"F Gomes","year":"2021","unstructured":"Gomes F, Faivre-Finn C, Mistry H, Bezjak A, Pourel N, Fournel P, et al. Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small-cell lung cancer - secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer. 2021;153:165\u201370. https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.025.","journal-title":"Lung Cancer"},{"key":"12556_CR18","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1200\/JCO.1995.13.7.1632","volume":"13","author":"PA Bunn Jr","year":"1995","unstructured":"Bunn PA Jr., Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995;13:1632\u201341. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1632.","journal-title":"J Clin Oncol"},{"key":"12556_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4103\/jcrt.JCRT_320_17","volume":"13","author":"F Liu","year":"2017","unstructured":"Liu F, Du Y, Cai B, Yan M, Yang W, Wang Q. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy. J Cancer Res Ther. 2017;13:790\u20135. https:\/\/doi.org\/10.4103\/jcrt.JCRT_320_17.","journal-title":"J Cancer Res Ther"},{"key":"12556_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00520-020-05906-y","volume":"29","author":"T Cooksley","year":"2021","unstructured":"Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R, et al. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer. 2021;29:1129\u201338. https:\/\/doi.org\/10.1007\/s00520-020-05906-y.","journal-title":"Support Care Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12556-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:05:39Z","timestamp":1720771539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12556-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12556"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12556-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of the Beijing Cancer Hospital (No: 2019YJZ27). This study was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR1900024494, 13\/07\/2019). Written informed consent was obtained from all patients before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients before participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"833"}}